FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Regeneron (NASDAQ: REGN) | Delayed: 805.67 -1.81 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $807.48 | 52 Week High | $592.36 | |||
| Open | $806.74 | 52 Week Low | $325.35 | |||
| Day High | $813.86 | P/E | 211.46 | |||
| Day Low | $800.24 | EPS | $3.81 | |||
| Volume | 581,048 | |||||
